Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%
Andreas Kuznik, Caitlin Smare, Chieh-I Chen, M. Venkatachalam, Sam Keeping, Kokuvi Atsou, Yingxin Xu, Florence R. Wilson, Patricia Guyot, Keith Chan, Emily Glowienka, Gerasimos Konidaris
Topics & Concepts
Lung cancerLine (geometry)OncologyLigand (biochemistry)MedicineExpression (computer science)Cancer researchInternal medicineIntensive care medicineComputer scienceMathematicsGeometryReceptorProgramming languageCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment